Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Current Liabilities (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Total Current Liabilities for 7 consecutive years, with $75.6 million as the latest value for Q2 2025.

  • On a quarterly basis, Total Current Liabilities changed N/A to $75.6 million in Q2 2025 year-over-year; TTM through May 2025 was $75.6 million, a N/A change, with the full-year FY2024 number at $95.9 million, up 10.23% from a year prior.
  • Total Current Liabilities was $75.6 million for Q2 2025 at Nurix Therapeutics, down from $95.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $95.9 million in Q4 2024 to a low of $46.8 million in Q2 2021.
  • A 5-year average of $68.8 million and a median of $67.5 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 55.12% in 2022, then fell 8.9% in 2023.
  • Nurix Therapeutics' Total Current Liabilities stood at $66.3 million in 2021, then increased by 6.64% to $70.7 million in 2022, then grew by 23.07% to $87.0 million in 2023, then grew by 10.23% to $95.9 million in 2024, then fell by 21.12% to $75.6 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Total Current Liabilities are $75.6 million (Q2 2025), $95.9 million (Q4 2024), and $86.3 million (Q3 2024).